Stay updated on Pembrolizumab in HR-Competent & Deficient Tumors Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in HR-Competent & Deficient Tumors Clinical Trial page.

Latest updates to the Pembrolizumab in HR-Competent & Deficient Tumors Clinical Trial page
- Check3 days agoChange DetectedThe page now displays a 403 Forbidden error for the study record, replacing the expected study details with the site’s standard error page.SummaryDifference17%

- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedThe page shows a new revision tag, v3.6.6, replacing the previous v3.6.5, indicating a platform update. This change does not modify the study data or visible details on the page.SummaryDifference0.1%

- Check38 days agoChange DetectedAdded the Study Protocol and Statistical Analysis Plan (PDF) to the Study Documents, along with IPD sharing information and related metadata such as source, last verified date, and publication notes.SummaryDifference45%

- Check45 days agoChange DetectedThe revision line in the page footer updated from v3.6.4 to v3.6.5, signaling a minor maintenance update.SummaryDifference0.1%

- Check60 days agoChange DetectedRevision label updated from v3.6.3 to v3.6.4, signaling a version upgrade of the page. The content and study details appear unchanged.SummaryDifference0.1%

- Check81 days agoChange DetectedThe page revision indicator was updated from v3.6.2 to v3.6.3, reflecting a new build of the page.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab in HR-Competent & Deficient Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in HR-Competent & Deficient Tumors Clinical Trial page.